Table 2.
Results from methylation quantifications of promoter regions in tumor Series A
| DCR2 (% meth) | CDH1 (%) | NORE1A (%) | P16 (%) | RARB (%) | RASSF1A (%) | LINE-1 (%) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Case no. | Tumor type | Metastatic disease | Mutation/syndrome | CIMP type | Z-scorea | MetI | Range | MetI | Range | MetI | Range | MetI | Range | MetI | Range | MetI | Range | MetI | Range |
| AG-1 | Pheo | No | MEN2 | – | −0.2 | 4 | 1–8 | 2 | 1–4 | 2 | 1–6 | 1 | 1–2 | 3 | 2–4 | 17 | 6–36 | 46 | 37–54 |
| AG-2 | Paraga | Met | SDHB | – | 0.5 | 15 | 11–26 | 11 | 4–18 | 3 | 1–7 | 10 | 8–13 | 4 | 3–7 | 7 | 7–8 | 75 | 74–77 |
| AG-3 | Pheo | No | RET | – | −0.4 | 3 | 1–7 | 3 | 1–15 | 2 | 1–6 | 1 | 1–1 | 3 | 2–4 | 2 | 1–3 | 68 | 65–73 |
| AG-4 | Pheo | No | NF1 | – | 0.1 | 21 | 6–33 | 4 | 1–6 | 2 | 2–5 | 2 | 0–9 | 3 | 0–5 | 10 | 7–15 | 75 | 71–77 |
| AG-5 | Pheo | No | NF1 | – | −0.4 | 4 | 2–9 | 3 | 1–6 | 2 | 1–6 | 1 | 1–2 | – | – | 3 | 2–3 | 71 | 66–75 |
| AG-6 | Paraga | No | SDHB | – | 0.2 | 12 | 6–20 | 8 | 2–20 | 3 | 1–6 | 9 | 3–17 | 2 | 1–3 | 11 | 5–20 | 77 | 75–78 |
| AG-7 | Pheo | No | NF1 | – | −0.2 | 13 | 4–22 | 4 | 1–7 | 2 | 1–5 | 1 | 1–2 | 2 | 1–3 | 7 | 3–11 | 74 | 70–76 |
| AG-8 | Pheo | No | RET | – | −0.5 | 2 | 1–4 | 3 | 1–5 | 2 | 1–5 | 1 | 1–2 | 2 | 1–3 | 2 | 1–3 | 76 | 71–81 |
| AG-9 | Paraga | Met | SDHB | CIMP | 2.8 | 49 | 22–64 | 4 | 1–7 | 6 | 3–11 | 50 | 40–57 | 21 | 4–37 | 42 | 39–47 | 68 | 64–74 |
| AG-10 | Pheo | No | – | – | 0.1 | 6 | 1–15 | 4 | 1–20 | 2 | 1–5 | 1 | 0–2 | 2 | 0–3 | 35 | 30–42 | 72 | 70–76 |
| AG-11 | Pheo | No | VHL | – | −0.3 | 4 | 1–5 | 4 | 1–7 | 2 | 1–4 | 1 | 1–2 | 3 | 2–3 | 2 | 1–3 | 80 | 76–83 |
| AG-12 | Pheo | No | VHL | – | −0.3 | 6 | 1–12 | 5 | 1–10 | 2 | 1–6 | 1 | 1–1 | 2 | 1–3 | 1 | 1–1 | 77 | 75–78 |
| AG-13 | Paraga | No | – | – | 0.5 | 25 | 6–43 | 5 | 2–8 | 2 | 1–5 | 29 | 15–49 | 2 | 0–4 | 12 | 8–16 | 78 | 75–81 |
| AG-14 | Paraga | Met | SDHB | CIMP | 2.8 | 50 | 34–58 | 24 | 5–53 | 8 | 3–27 | 40 | 32–47 | 2 | 2–4 | 28 | 25–33 | 79 | 78–79 |
| AG-15 | Pheo | No | NF1 | – | −0.3 | 3 | 1–5 | 4 | 2–5 | 2 | 1–4 | 1 | 1–2 | – | – | 13 | 4–33 | 73 | 68–76 |
| AG-16 | Paraga | No | – | – | −0.4 | 3 | 1–4 | 3 | 2–5 | 2 | 1–6 | 1 | 1–1 | – | – | 8 | 4–15 | 76 | 72–78 |
| AG-17 | Pheo | No | RET | – | 0.0 | 7 | 2–13 | 5 | 2–8 | 4 | 1–11 | 1 | 1–2 | 4 | 3–5 | 3 | 2–4 | 77 | 75–79 |
| AG-18a | Paraga | Met | – | – | 0.6 | 13 | 7–18 | 5 | 2–8 | 2 | 1–6 | 21 | 18–25 | – | – | 30 | 27–33 | 72 | 70–73 |
| AG-18b | Paraga | – | – | – | 16 | 3–34 | 4 | 2–8 | 4 | 2–11 | 1 | 1–2 | 3 | 2–6 | 3 | 2–4 | 76 | 73–79 | |
| AG-19 | Pheo | No | RET | – | −0.3 | 5 | 2–11 | 2 | 1–5 | 3 | 1–11 | 4 | 1–14 | 2 | 0–3 | 2 | 1–3 | 70 | 66–74 |
| AG-20 | Paraga | No | SDHB | CIMP | 1.3 | 45 | 17–69 | 4 | 1–6 | 2 | 1–7 | 40 | 14–59 | 3 | 2–5 | 32 | 15–51 | 64 | 61–70 |
| AS-21 | Paraga | Met | SDHB | – | 0.6 | 27 | 6–48 | 6 | 2–8 | 2 | 1–6 | 8 | 4–12 | 8 | 2–25 | 17 | 8–28 | 76 | 70–74 |
| AS-22 | Pheo | No | RET | – | −0.4 | 4 | 0–11 | 3 | 0–7 | 2 | 0–8 | 2 | 0–6 | 0 | 0–0 | 9 | 1–30 | 62 | 57–66 |
| AS-23 | Pheo | No | – | – | −0.3 | 2 | 0–14 | 8 | 0–29 | 2 | 0–6 | 0 | 0–1 | 1 | 0–4 | 9 | 0–21 | 64 | 57–70 |
| AS-24 | Pheo | No | NF1 | – | −0.6 | 5 | 2–11 | 5 | 3–8 | 0 | 0–4 | 2 | 0–4 | 1 | 0–4 | 2 | 0–4 | 61 | 58–63 |
| AS-25 | Pheo | No | MEN2 | – | −0.7 | 2 | 0–6 | 1 | 0–5 | 1 | 0–3 | 0 | 0–1 | 0 | 0–3 | 8 | 6–11 | 51 | 46–57 |
| AS-26 | Pheo | No | RET | – | −0.4 | 11 | 4–17 | 2 | 0–7 | 1 | 0–4 | 2 | 1–3 | 2 | 0–5 | 7 | 1–20 | 59 | 57–61 |
| AS-27 | Pheo | No | RET | – | −0.5 | 1 | 0–3 | 6 | 0–45 | 1 | 0–6 | 0 | 0–1 | 0 | 0–4 | 0 | 0–1 | 63 | 58–68 |
| AS-28 | Pheo | No | – | – | −0.3 | 5 | 2–11 | 6 | 3–9 | 1 | 0–4 | 2 | 0–4 | 3 | 0–9 | 2 | 0–4 | 63 | 59–65 |
| AS-29 | Pheo | No | – | – | −0.3 | 10 | 0–47 | 2 | 0–4 | 2 | 0–5 | 2 | 1–4 | 2 | 0–8 | 11 | 4–34 | 59 | 53–63 |
| AS-30 | Pheo | No | – | – | −0.5 | 1 | 0–4 | – | – | 1 | 0–5 | 0 | 0–1 | 0 | 0–4 | 12 | 4–24 | 61 | 58–65 |
| AS-31 | Pheo | No | – | – | 0.2 | 16 | 3–58 | 6 | 0–23 | 1 | 0–5 | 1 | 0–1 | 0 | 0–4 | 38 | 22–50 | 56 | 53–58 |
| AS-32 | Pheo | No | – | – | −0.2 | 2 | 0–5 | 14 | 4–34 | 1 | 0–4 | 1 | 0–3 | 0 | 0–0 | 3 | 3–5 | 63 | 58–67 |
| AS-33 | Pheo | No | – | – | −0.5 | 11 | 0–24 | 3 | 0–7 | 1 | 0–4 | 1 | 0–1 | 0 | 0–4 | 1 | 1–2 | 66 | 64–67 |
| AS-34 | Pheo | No | – | – | −0.4 | 19 | 5–35 | 3 | 0–5 | 1 | 0–5 | 1 | 1–2 | 1 | 0–3 | 8 | 5–11 | 64 | 60–67 |
| AS-35 | Pheo | No | – | – | −0.5 | 1 | 0–4 | 4 | 0–15 | 1 | 0–5 | 2 | 0–8 | 1 | 0–6 | 1 | 1–1 | 60 | 56–63 |
| AS-36 | Pheo | No | – | – | −0.3 | 9 | 0–32 | 2 | 0–3 | 1 | 0–5 | 0 | 0–1 | 0 | 0–0 | 24 | 4–39 | 54 | 47–57 |
| AS-37 | Paraga | No | – | – | −0.4 | 2 | 0–5 | 3 | 0–7 | 2 | 0–7 | 1 | 0–5 | 1 | 0–5 | 12 | 0–38 | 68 | 65–74 |
| AS-38 | Paraga | Met | – | – | −0.2 | 3 | 1–6 | – | – | 3 | 0–7 | 1 | 0–1 | 0 | 0–2 | 14 | 6–17 | 53 | 49–55 |
| AS-39 | Paraga | No | – | – | −0.3 | 3 | 0–5 | 7 | 3–10 | 1 | 0–4 | 2 | 0–3 | 4 | 2–6 | 0 | 0–1 | 66 | 64–67 |
| Reference values | |||||||||||||||||||
| Cutoff (%) | >30 | >30 | >10 | >10 | >10 | >10 | >10 | >10 | >10 | >10 | >30 | >30 | |||||||
meth, methylation; range, minimum–maximum value detected at an individual. CpG G-18a and G-18b are primary tumor and metastasis from the same patient.